These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up. Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114 [TBL] [Abstract][Full Text] [Related]
6. Apatinib-treated advanced medullary thyroid carcinoma: a case report. Chen K; Gao Y; Shi F; Cao G; Bao J Onco Targets Ther; 2018; 11():459-463. PubMed ID: 29403290 [TBL] [Abstract][Full Text] [Related]
7. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914 [No Abstract] [Full Text] [Related]
8. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373 [TBL] [Abstract][Full Text] [Related]
9. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032 [TBL] [Abstract][Full Text] [Related]
10. The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment. Siano M; Alfieri S; Granata R; Calareso G; Orlandi E; Bergamini C; Locati LD Tumori; 2019 Dec; 105(6):NP28-NP31. PubMed ID: 30782103 [TBL] [Abstract][Full Text] [Related]
11. Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells. Starenki D; Hong SK; Wu PK; Park JI Cancer Biol Ther; 2017 Jul; 18(7):473-483. PubMed ID: 28475408 [TBL] [Abstract][Full Text] [Related]
12. cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib. Prescrire Int; 2016 Jan; 25(167):11-3. PubMed ID: 26942253 [TBL] [Abstract][Full Text] [Related]
13. Recent Updates on the Management of Medullary Thyroid Carcinoma. Kim BH; Kim IJ Endocrinol Metab (Seoul); 2016 Sep; 31(3):392-399. PubMed ID: 27586449 [TBL] [Abstract][Full Text] [Related]
14. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. Viola D; Cappagli V; Elisei R Future Oncol; 2013 Aug; 9(8):1083-92. PubMed ID: 23902240 [TBL] [Abstract][Full Text] [Related]
15. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. Krajewska J; Olczyk T; Jarzab B Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165 [TBL] [Abstract][Full Text] [Related]
16. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560 [TBL] [Abstract][Full Text] [Related]
17. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure. Coquan E; Brachet PE; Licaj I; Leconte A; Castera M; Lequesne J; Meriaux E; Bonnet I; Lelaidier A; Clarisse B; Joly F BMC Cancer; 2021 Sep; 21(1):1054. PubMed ID: 34563169 [TBL] [Abstract][Full Text] [Related]
18. Metastatic medullary thyroid cancer: a dramatic response to a systemic chemotherapy (temozolomide and capecitabine) regimen. Lacin S; Esin E; Karakas Y; Yalcin S Onco Targets Ther; 2015; 8():1039-42. PubMed ID: 25999738 [TBL] [Abstract][Full Text] [Related]
19. Gastropharyngeal Anastomotic Leak in Medullary Thyroid Carcinoma Following Initiation of a Tyrosine Kinase Inhibitor: A Case Report of an Unusual Side Effect of Cabozantinib. Ackerman J; Kent S; Walker P Ann Otol Rhinol Laryngol; 2020 Jul; 129(7):657-661. PubMed ID: 32037846 [TBL] [Abstract][Full Text] [Related]
20. Unusual gastric mucosal infiltration by a medullary thyroid carcinoma: a case report. Karrasch T; Doppl W; Roller FC; Schäffler A; Schäffer R; Gattenlöhner S J Med Case Rep; 2016 Jul; 10():208. PubMed ID: 27461534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]